Evdokiou A - Search Results

1

Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling.

Pishas KI, Neuhaus SJ, Clayer MT, Schreiber AW, Lawrence DM, Perugini M, Whitfield RJ, Farshid G, Manavis J, Chryssidis S, Mayo BJ, Haycox RC, Ho K, Brown MP, D'Andrea RJ, Evdokiou A, Thomas DM, Desai J, Callen DF, Neilsen PM. Pishas KI, et al. Among authors: evdokiou a. Cancer Res. 2014 Feb 1;74(3):921-31. doi: 10.1158/0008-5472.CAN-13-2424. Epub 2013 Dec 13. Cancer Res. 2014. PMID: 24336067

2

Tumor-suppressive activity of the growth arrest-specific gene GAS1 in human tumor cell lines.

Evdokiou A, Cowled PA. Evdokiou A, et al. Int J Cancer. 1998 Feb 9;75(4):568-77. doi: 10.1002/(sici)1097-0215(19980209)75:4<568::aid-ijc13>3.0.co;2-5. Int J Cancer. 1998. PMID: 9466658 Free article.

3

Expression of alternatively-spliced MDM2 transcripts in giant cell tumours of bone.

Evdokiou A, Atkins GJ, Bouralexis S, Hay S, Raggatt LJ, Cowled PA, Graves SE, Clayer M, Findlay DM. Evdokiou A, et al. Int J Oncol. 2001 Sep;19(3):625-32. doi: 10.3892/ijo.19.3.625. Int J Oncol. 2001. PMID: 11494046

4

Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis.

Evdokiou A, Bouralexis S, Atkins GJ, Chai F, Hay S, Clayer M, Findlay DM. Evdokiou A, et al. Int J Cancer. 2002 Jun 1;99(4):491-504. doi: 10.1002/ijc.10376. Int J Cancer. 2002. PMID: 11992538 Free article.

5

Enhanced apoptosis of soft tissue sarcoma cells with chemotherapy: A potential new approach using TRAIL.

Clayer M, Bouralexis S, Evdokiou A, Hay S, Atkins GJ, Findlay DM. Clayer M, et al. Among authors: evdokiou a. J Orthop Surg (Hong Kong). 2001 Dec;9(2):19-22. doi: 10.1177/230949900100900205. J Orthop Surg (Hong Kong). 2001. PMID: 12118126 Free article.

6

Sensitivity of fresh isolates of soft tissue sarcoma, osteosarcoma and giant cell tumour cells to Apo2L/TRAIL and doxorubicin.

Bouralexis S, Clayer M, Atkins GJ, Labrinidis A, Hay S, Graves S, Findlay DM, Evdokiou A. Bouralexis S, et al. Among authors: evdokiou a. Int J Oncol. 2004 May;24(5):1263-70. doi: 10.3892/ijo.24.5.1263. Int J Oncol. 2004. PMID: 15067350

7

Apo2l/Tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model.

Thai le M, Labrinidis A, Hay S, Liapis V, Bouralexis S, Welldon K, Coventry BJ, Findlay DM, Evdokiou A. Thai le M, et al. Among authors: evdokiou a. Cancer Res. 2006 May 15;66(10):5363-70. doi: 10.1158/0008-5472.CAN-05-4386. Cancer Res. 2006. PMID: 16707463

8

Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma.

Labrinidis A, Diamond P, Martin S, Hay S, Liapis V, Zinonos I, Sims NA, Atkins GJ, Vincent C, Ponomarev V, Findlay DM, Zannettino AC, Evdokiou A. Labrinidis A, et al. Among authors: evdokiou a. Clin Cancer Res. 2009 Mar 15;15(6):1998-2009. doi: 10.1158/1078-0432.CCR-08-2444. Epub 2009 Mar 10. Clin Cancer Res. 2009. PMID: 19276263 Free PMC article.

9

Nutlin-3a is a potential therapeutic for ewing sarcoma.

Pishas KI, Al-Ejeh F, Zinonos I, Kumar R, Evdokiou A, Brown MP, Callen DF, Neilsen PM. Pishas KI, et al. Among authors: evdokiou a. Clin Cancer Res. 2011 Feb 1;17(3):494-504. doi: 10.1158/1078-0432.CCR-10-1587. Epub 2010 Nov 23. Clin Cancer Res. 2011. PMID: 21098696

10

RECK in osteosarcoma: a novel role in tumour vasculature and inhibition of tumorigenesis in an orthotopic model.

Clark JC, Akiyama T, Thomas DM, Labrinidis A, Evdokiou A, Galloway SJ, Kim HS, Dass CR, Choong PF. Clark JC, et al. Among authors: evdokiou a. Cancer. 2011 Aug 1;117(15):3517-28. doi: 10.1002/cncr.25757. Epub 2011 Feb 1. Cancer. 2011. PMID: 21287525 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

102 results

Search Page